KRAS and ovarian mucinous neoplasm: Particularly, Lee and coworkers have analyzed a set of mucinous ovarian tumors and have shown a prevalence of KRAS mutations of 0% in normal epithelial ovarian tissue, 57% in mucinous benign tumors, 90% in borderline mucinous neoplasms and 76% in malignant mucinous carcinomas [113].